Alpha Tau Medical announced that its clinical trial data on combining Alpha DaRT, a targeted alpha-radiation therapy, with pembrolizumab for elderly patients with advanced head and neck squamous cell carcinoma will be presented at the AHNS 12th International Conference in July 2026. This combination aims to enhance immune response and improve outcomes for patients who often cannot tolerate aggressive treatments. The trial builds on prior monotherapy studies and highlights Alpha DaRT's safety and potential as an add-on to immunotherapy without increasing toxicity. The presentation marks a key milestone in advancing treatment options for this challenging patient group.
Polaris Inc. reported a strong quarterly performance with earnings per share of $1.97, beating estimates by over 155%, and revenues of $2.02 billion, up 9.2% year-over-year. The growth was driven by sales recovery in the utility off-road vehicle segm...
Seagate Technology is set to report its Q2 2026 earnings with analysts expecting an EPS of $5.10 and revenue around $3.5 billion, reflecting strong demand for data storage driven by AI growth. The company's optimistic guidance aligns with these estim...
Teladoc Health, a leader in virtual healthcare services, has seen its average analyst price target rise from $8.35 to $11.00, reflecting increased confidence in its market position. The stock recently jumped 6.1% with high trading volume, driven by r...
Procter & Gamble, a leading consumer goods company and Dividend King, is seeing a decline in analyst price targets from $162.52 to $152 over the past year, though Deutsche Bank remains optimistic with a $177 target. Despite a strong history of beatin...
Cognizant Technology Solutions has seen a decline in analyst price targets from $74.94 to $56.33 over the past year, reflecting increased caution about its stock performance. Despite this, some analysts remain optimistic, with a notable price target ...
